Single answer
Is ArriVent BioPharma Inc Common (AVBP) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
What is the conclusion?
Right now our advanced algorithms say:
Do analysts agree?
We compare consensus targets with today's price.
Consensus target for ArriVent BioPharma Inc Common Stock is $40.33, which is $19.61 (94.64%) above the current price today's price.
Low target: $33.00 | High target: $45.00
Company snapshot
A quick overview of the business and its public profile.
ArriVent BioPharma Inc operates as a clinicalstage biopharmaceutical company that engages in the identification development and commercialization of medicines for the unmet medical needs of patients with cancers It also engages in the development and commercialization of targeted cancer therapies for nonsmallcell lung cancer NSCLC and other solid tumors The company develops Furmonertinib an epidermal growth factor receptor mutantselective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients and ARR002 It has strategic collaborations with Aarvik Therapeutics Inc The company was incorporated in 2021 and is based in Newtown Square Pennsylvania
Website: https://www.arrivent.com
Rates and inflation backdrop
US inflation for September 2025 was 0.31%. Over the last 12 months, inflation is 3.02%. The 10-year yield is 4.12 and is down -0.1000 over the last 30 days.
Inflation sensitivity
Debt ratio: 0.00. Cash flow to debt ratio: -1,292.13. Net profit margin: 0.00%. Inflation risk score: medium (0.60/1).
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
Yes, the average daily trading liquidity for ArriVent BioPharma Inc Common is $7.1M. You should therefore be able to get in and out of your positions relatively fast.
10-year return check
We cannot find data for ArriVent BioPharma Inc Common 10 years ago, but if you had invested on 2024-01-26 when the price was $20.00, you would have made a profit of $0.720 per share or 3.60%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.